A Perioperative Warning: Reassessing Antidepressant Risks in Surgery
A recent correspondence in The Lancet challenges the reassuring findings of a major network meta-analysis on antidepressant side effects, specifically regarding corrected QT interval (QTc) prolongation and hyponatraemia. The authors argue that data from acute, low-risk outpatient trials may not translate to the high-stakes perioperative environment, where factors like fluid shifts, electrolyte imbalances, and polypharmacy can significantly amplify these specific cardiovascular and metabolic risks. This critical perspective urges surgeons, anesthesiologists, and perioperative physicians to exercise heightened vigilance and personalized risk assessment for patients on antidepressants undergoing surgery, moving beyond generalized conclusions to consider the unique physiological stressors of the operative setting.
Study Significance: For surgical teams, this highlights a crucial gap in perioperative medication safety protocols, emphasizing that preoperative assessment must account for drug-specific risks that are magnified during surgery. It underscores the need for tailored guidelines that integrate pharmacological risk profiles with surgical and anesthetic stressors to optimize patient outcomes and prevent postoperative complications related to cardiac arrhythmias and electrolyte disorders.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
